Imagine a loved one is in a Phase III trial for a new cancer drug. Every day, you refresh the hospital portal, waiting for news. Now imagine that strangers on the internet are betting on whether that drug will fail—and they might know the answer before the doctors do.
This isn’t a dystopian novel. It’s real. Kalshi and Polymarket have started taking bets on Phase III clinical trial outcomes. And the uncomfortable truth is that these markets only become accurate if we let people trade on non-public information.
Prediction markets are only truth machines if we let insiders lie.
You’ve probably heard the hype: prediction markets are supposed to aggregate information better than experts, turning crowds into oracles. But here’s the catch—the mechanism that makes them efficient is the same mechanism that securities law calls a felony.
Let’s break it down.
A Phase III trial is a controlled, double-blind study. The data is secret until the official readout. If a nurse, a data monitor, or a patient’s doctor sees early signals that the drug is working (or tanking), they have an information edge. In a well-functioning prediction market, that edge should be priced in. The market price would reflect the truth faster than the FDA can issue a press release.
But that’s insider trading. And under current SEC rules, trading on material non-public information is illegal.
So we have a paradox: the market is only useful if it is legally unacceptable.
If you ban insider trading, the market degrades into a casino. The odds become a popularity contest, not a signal. And if you allow it, you’re asking regulators to bless a practice they’ve spent decades prosecuting.
This is not a theoretical debate. The SEC and the FDA are about to collide over whether clinical trial results are protected secrets or signals that should be allowed to move money before the official announcement.
History is on the side of the gamblers. Early stock exchanges were dismissed as gambling dens before legal frameworks legitimized them. The same could happen here—but only if we’re willing to rewrite the rules.
Most people see insider trading as cheating. In prediction markets, it’s the lubrication that makes the engine run. If you want accurate prices, you have to let the people who know the most bet the most.
The real fight will be whether the FDA and SEC treat clinical trial results as protected secrets or as signals that should be allowed to move money before the official announcement. The outcome will determine whether these markets become a tool for saving lives or just another vehicle for gambling on hope.
And if you’re a patient waiting for a cure, you should be paying attention. Because the betting line may know the answer before your doctor does.
FAQ
Q: Why can't prediction markets work without insider trading?
A: Because the most accurate information about a trial's outcome is held by insiders—doctors, nurses, data monitors—who know the unblinded results. If they can't trade, the market relies on public speculation, which is no better than a weather forecast from a random person.
Q: What would happen if the SEC allowed insider trading in these markets?
A: Prices would likely become very accurate, potentially predicting trial outcomes weeks or months before official announcements. But it would also create a two-tier system where insiders profit from patient data, raising ethical concerns about fairness and exploitation.
Q: Isn't this just gambling on people's suffering?
A: It looks that way, but the counterargument is that accurate prices can help investors allocate capital to promising drugs faster, and even alert regulators to safety signals earlier. The real question is whether the benefit of faster, cheaper drug development outweighs the discomfort of commodifying hope.